(19)
(11) EP 2 443 250 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.09.2016 Bulletin 2016/38

(45) Mention of the grant of the patent:
20.07.2016 Bulletin 2016/29

(21) Application number: 10771227.5

(22) Date of filing: 16.06.2010
(51) International Patent Classification (IPC): 
C12Q 1/04(2006.01)
(86) International application number:
PCT/US2010/038872
(87) International publication number:
WO 2011/008400 (20.01.2011 Gazette 2011/03)

(54)

HIGH-THROUGHPUT COMPLEMENT-MEDIATED ANTIBODY-DEPENDENT AND OPSONIC BACTERICIDAL ASSAYS

KOMPLEMENT-VERMITTELTE ANTIKÖRPER-ABHÄNGIGE UND OPSONISCHE BAKTERIENASSAYS MIT HOHEM DURCHLAUF

DOSAGES HAUT DÉBIT DE BACTÉRICIDES OPSONIQUES ET DÉPENDANT D'ANTICORPS À MÉDIATION PAR LE COMPLÉMENT

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 16.06.2009 US 187630 P

(43) Date of publication of application:
25.04.2012 Bulletin 2012/17

(73) Proprietor: GlaxoSmithKline Biologicals SA
1330 Rixensart (BE)

(72) Inventors:
  • MAK, Puiying, Annie
    San Diego, CA 92121 (US)
  • SANTOS, George
    Emeryville, CA 94662-8097 (US)
  • JANES, Jeffrey, Eugene
    San Diego, CA 92121 (US)
  • DONNELLY, John
    Emeryville, CA 94662-8097 (US)

(74) Representative: Pontremoli, Guido 
GlaxoSmithKline SA Global Patents CN925.1 980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB)


(56) References cited: : 
   
  • SANTOS G F ET AL: "Importance of complement source in measuring meningococcal bactericidal titers.", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY MAY 2001 LNKD- PUBMED:11329468, vol. 8, no. 3, May 2001 (2001-05), pages 616-623, XP002616616, ISSN: 1071-412X cited in the application
  • MOUNTZOUROS K T ET AL: "Detection of complement-mediated antibody-dependent bactericidal activity in a fluorescence-based serum bactericidal assay for group B Neisseria meningitidis", JOURNAL OF CLINICAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 38, no. 8, 1 August 2000 (2000-08-01) , pages 2878-2884, XP002500285, ISSN: 0095-1137 cited in the application
  • ROMERO-STEINER SANDRA ET AL: "Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 11, no. 1, 1 January 2004 (2004-01-01), pages 89-93, XP002500286, ISSN: 1071-412X, DOI: DOI:10.1128/CDLI.11.1.89-93.2004 cited in the application
  • BIEGING KATHRYN T ET AL: "Fluorescent multivalent opsonophagocytic assay for measurement of functional antibodies to Streptococcus pneumoniae", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 12, no. 10, 1 October 2005 (2005-10-01), pages 1238-1242, XP002500288, ISSN: 1071-412X, DOI: DOI:10.1128/CDLI.12.10.1238-1242.2005
  • RODRIGUEZ T ET AL: "Standardization of Neisseria meningitidis serogroup B colorimetric serum bactericidal assay", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 9, no. 1, 1 January 2002 (2002-01-01) , pages 109-114, XP003009515, ISSN: 1071-412X, DOI: DOI:10.1128/CDLI.9.1.109-114.2002
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).